TOP > 外国特許検索 > DIAGNOSTIC OF RHEUMATOID ARTHRITIS

DIAGNOSTIC OF RHEUMATOID ARTHRITIS NEW

外国特許コード F190009769
整理番号 (S2017-0877-N0)
掲載日 2019年5月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP025020
国際公開番号 WO 2019009231
国際出願日 平成30年7月2日(2018.7.2)
国際公開日 平成31年1月10日(2019.1.10)
優先権データ
  • 特願2017-132888 (2017.7.6) JP
  • 特願2018-005038 (2018.1.16) JP
発明の名称 (英語) DIAGNOSTIC OF RHEUMATOID ARTHRITIS NEW
発明の概要(英語) Provided are: a method for diagnosis of rheumatoid arthritis in a subject; a method for auxiliary diagnosis of rheumatoid arthritis; and a method for monitoring disease activity of rheumatoid arthritis and/or a therapeutic effect of a rheumatoid arthritis drug, each method being characterized by comprising detecting citrullination of an arginine residue in inter-α-trypsin inhibitor heavy chain (ITIH) 4 in a biological sample derived from the subject. Also provided are: a citrullinated protein, wherein, in a protein having the amino acid sequence represented by SEQ ID NO: 1 or 5, the 438-th arginine residue has been modified into a citrulline residue, or a fragment of said protein; an antibody capable of binding to the citrullinated protein; and a diagnostic of rheumatoid arthritis which comprises the antibody.
従来技術、競合技術の概要(英語) BACKGROUND ART
(Rheumatoid Arthritis, RA) is rheumatoid arthritis, joint pain and swelling occurs, further deformation of the joint, and then proceeds to the destruction of the autoimmune disease is an inflammatory. Is RA, joint pain and swelling, the presence or absence of an inflammatory response, the duration of the arthritis, and total blood test values or the like described later are diagnosed, it may not be determined previously and arthritis long known that the presence of pre-clinical stage, the development of RA is the environmental risk factors and genetic risk factors have been reported to be involved in the (non-patent document 1).
RA is the body of the patient anti-citrullinated protein binds to citrullinated peptide antibody (anti-citrullinated protein antibodies, ACPA) is known to exist (non-patent document 2). In addition, in the RA of the patient's joint is increased and a plurality of types of citrullinated protein and, which may be involved in the RA has been suggested (Non-Patent Document 3-5). However, major serum proteins citrulline, and its role in the pathogenesis of relevance is not clear.
For treatment of RA, inflammation and pain drug treatment, surgery, rehabilitation and the like are performed, in recent years, anti-cytokine therapy to onset of clinical remission can be obtained from the reported cases, early diagnosis, early treatment are required.
Comprehensive clinical symptoms of RA as an index, for example the evaluation of the joint 28 has been used widely DAS(Disease Activity Score) 28. DAS28 In, blood laboratory values inflammatory response C-reactive protein (CRP) as those used in DAS28-CRP. Other, rheumatoid factor and an index value of the ACPA blood test for the diagnosis of RA have been used to, rheumatoid factor is compared to the high accuracy of the ACPA detected by the (non-patent document 6).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF TSUKUBA
  • 発明者(英語)
  • MATSUMOTO Isao
  • SUMIDA Takayuki
  • KAWAGUCHI Hoshimi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
この特許について質問等ある場合は、電子メールによりご連絡ください。

PAGE TOP

close
close
close
close
close
close